vs
READING INTERNATIONAL INC（RDI）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是ARS Pharmaceuticals, Inc.的1.8倍（$50.3M vs $28.1M），READING INTERNATIONAL INC净利率更高（-5.1% vs -147.1%，领先142.0%），READING INTERNATIONAL INC同比增速更快（-14.2% vs -67.6%）
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
RDI vs SPRY — 直观对比
营收规模更大
RDI
是对方的1.8倍
$28.1M
营收增速更快
RDI
高出53.4%
-67.6%
净利率更高
RDI
高出142.0%
-147.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.3M | $28.1M |
| 净利润 | $-2.6M | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | -1.9% | -147.6% |
| 净利率 | -5.1% | -147.1% |
| 营收同比 | -14.2% | -67.6% |
| 净利润同比 | -14.5% | -182.8% |
| 每股收益（稀释后） | $-0.11 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RDISPRY
| Q4 25 | $50.3M | $28.1M | ||
| Q3 25 | $52.2M | $32.5M | ||
| Q2 25 | $60.4M | $15.7M | ||
| Q1 25 | $40.2M | $8.0M | ||
| Q4 24 | $58.6M | $86.6M | ||
| Q3 24 | $60.1M | $2.1M | ||
| Q2 24 | $46.8M | $500.0K | ||
| Q1 24 | $45.1M | $0 |
净利润RDISPRY
| Q4 25 | $-2.6M | $-41.3M | ||
| Q3 25 | $-4.2M | $-51.2M | ||
| Q2 25 | $-2.7M | $-44.9M | ||
| Q1 25 | $-4.8M | $-33.9M | ||
| Q4 24 | $-2.2M | $49.9M | ||
| Q3 24 | $-7.0M | $-19.1M | ||
| Q2 24 | $-12.8M | $-12.5M | ||
| Q1 24 | $-13.2M | $-10.3M |
营业利润率RDISPRY
| Q4 25 | -1.9% | -147.6% | ||
| Q3 25 | -0.6% | -163.7% | ||
| Q2 25 | 4.8% | -302.9% | ||
| Q1 25 | -17.2% | -466.3% | ||
| Q4 24 | 2.6% | 54.5% | ||
| Q3 24 | -0.6% | -1051.6% | ||
| Q2 24 | -16.4% | -3068.0% | ||
| Q1 24 | -16.7% | — |
净利率RDISPRY
| Q4 25 | -5.1% | -147.1% | ||
| Q3 25 | -8.0% | -157.4% | ||
| Q2 25 | -4.4% | -285.6% | ||
| Q1 25 | -11.8% | -425.7% | ||
| Q4 24 | -3.8% | 57.7% | ||
| Q3 24 | -11.7% | -925.0% | ||
| Q2 24 | -27.4% | -2503.2% | ||
| Q1 24 | -29.4% | — |
每股收益（稀释后）RDISPRY
| Q4 25 | $-0.11 | $-0.41 | ||
| Q3 25 | $-0.18 | $-0.52 | ||
| Q2 25 | $-0.12 | $-0.46 | ||
| Q1 25 | $-0.21 | $-0.35 | ||
| Q4 24 | $-0.11 | $0.52 | ||
| Q3 24 | $-0.31 | $-0.20 | ||
| Q2 24 | $-0.57 | $-0.13 | ||
| Q1 24 | $-0.59 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.5M | $245.0M |
| 总债务越低越好 | $185.1M | $96.4M |
| 股东权益账面价值 | $-18.2M | $114.3M |
| 总资产 | $434.9M | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资RDISPRY
| Q4 25 | $10.5M | $245.0M | ||
| Q3 25 | $8.1M | $288.2M | ||
| Q2 25 | $9.1M | $240.1M | ||
| Q1 25 | $5.9M | $275.7M | ||
| Q4 24 | $12.4M | $314.0M | ||
| Q3 24 | $10.1M | $204.6M | ||
| Q2 24 | $9.3M | $218.7M | ||
| Q1 24 | $7.5M | $223.6M |
总债务RDISPRY
| Q4 25 | $185.1M | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $202.7M | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RDISPRY
| Q4 25 | $-18.2M | $114.3M | ||
| Q3 25 | $-12.1M | $147.7M | ||
| Q2 25 | $-7.7M | $192.3M | ||
| Q1 25 | $-8.1M | $229.0M | ||
| Q4 24 | $-4.4M | $256.8M | ||
| Q3 24 | $1.6M | $201.0M | ||
| Q2 24 | $6.5M | $215.2M | ||
| Q1 24 | $18.0M | $223.9M |
总资产RDISPRY
| Q4 25 | $434.9M | $327.7M | ||
| Q3 25 | $435.2M | $372.8M | ||
| Q2 25 | $438.1M | $313.5M | ||
| Q1 25 | $441.0M | $327.3M | ||
| Q4 24 | $471.0M | $351.2M | ||
| Q3 24 | $495.7M | $217.6M | ||
| Q2 24 | $494.9M | $222.0M | ||
| Q1 24 | $494.9M | $227.6M |
负债/权益比RDISPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | $4.1M | — |
| 自由现金流率自由现金流/营收 | 8.2% | — |
| 资本支出强度资本支出/营收 | 0.3% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-2.9M | — |
8季度趋势，按日历期对齐
经营现金流RDISPRY
| Q4 25 | $4.3M | $-43.5M | ||
| Q3 25 | $295.0K | $-47.0M | ||
| Q2 25 | $1.6M | $-39.6M | ||
| Q1 25 | $-7.7M | $-40.7M | ||
| Q4 24 | $8.0M | $42.0M | ||
| Q3 24 | $1.3M | $-14.5M | ||
| Q2 24 | $-10.4M | $-7.3M | ||
| Q1 24 | $-2.8M | $-6.7M |
自由现金流RDISPRY
| Q4 25 | $4.1M | — | ||
| Q3 25 | $-246.0K | $-47.2M | ||
| Q2 25 | $1.2M | $-39.6M | ||
| Q1 25 | $-8.0M | $-40.8M | ||
| Q4 24 | $7.0M | $41.7M | ||
| Q3 24 | $-1.1M | $-14.6M | ||
| Q2 24 | $-10.6M | $-7.3M | ||
| Q1 24 | $-4.7M | $-6.8M |
自由现金流率RDISPRY
| Q4 25 | 8.2% | — | ||
| Q3 25 | -0.5% | -145.4% | ||
| Q2 25 | 1.9% | -252.2% | ||
| Q1 25 | -19.8% | -512.1% | ||
| Q4 24 | 12.0% | 48.2% | ||
| Q3 24 | -1.8% | -706.3% | ||
| Q2 24 | -22.7% | -1463.4% | ||
| Q1 24 | -10.4% | — |
资本支出强度RDISPRY
| Q4 25 | 0.3% | 0.0% | ||
| Q3 25 | 1.0% | 0.6% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 0.6% | 1.1% | ||
| Q4 24 | 1.7% | 0.3% | ||
| Q3 24 | 4.0% | 6.8% | ||
| Q2 24 | 0.5% | 7.6% | ||
| Q1 24 | 4.3% | — |
现金转化率RDISPRY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
